| 摘要: |
| [摘要] 目的:比较3% 高渗盐水和重组人干扰素α-2b雾化吸入辅助治疗轻中度毛细支气管炎患儿的疗效。 方法:收集 2015 年
11 月至 2017 年 4 月在安徽医科大学附属安庆医院儿科住院治疗的轻中度毛细支气管炎患儿 134 例,随机分为三组:对照组给予沙丁胺醇
2.5 mg+布地奈德 0.5 mg 用生理盐水配成 2.5 mL 雾化吸入,每日 2 次;高渗盐水组在对照组基础上给予 3% 高渗盐水
4 mL 雾化吸入,间隔 4 h 一次,每日 3 次;干扰素组在对照组雾化方案中加入重组人干扰素 琢鄄2b 200 000 IU / kg,每日 2 次。 记录患儿治疗前及治疗后
5 d 内的临床病情严重程度评分、不良反应发生情况、退出研究例数和住院时间。 结果:对照组 3 例、高渗盐水组2 例、干扰素组 2 例因病情加重加用其他药物治疗后退出(P>0.05)。 高渗盐水组 4 例因阵发性刺激性咳嗽退出, 干扰素组和对照组未出现明显不良反应(P
<0.05)。 最终完成研究 123 例,其中对照组 40 例,高渗盐水组 42 例,干扰素组 41
例。 高渗盐水组病情严重程度评分在治疗后第
2-4 天低于干扰素组,在第 2-5 天低于对照组(P 均<0.01);干扰素组病情严重程度评分在第4-5 天低于对照组(P 均<0.01)。 高渗盐水组和干扰素组的住院时间均短于对照组(P 均<0.05)。 结论:雾化吸入
3% 高渗盐水和重组人干扰素α-2b均能改善轻中度毛细支气管炎患儿的病情,缩短住院时间,但前者可引起刺激性咳
嗽。 |
| 关键词: 毛细支气管炎 高渗盐水 重组人干扰素α-2b 雾化吸入 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.03.009 |
|
| 基金项目: |
|
| Therapeutic Effect of Atomization Inhalation of 3% Hypertonic Saline and Recombinant Human Interferon α-2b in the Treatment of Mild to Moderate Bronchiolitis |
| Xu Senmao, Cheng Xiangao |
| (Anqing Hospital Affiliated to Anhui Medical University, Anhui Anqing 246003, China) |
| Abstract: |
| [Abstract] Objective: To compare the therapeutic efficacy of atomization inhalation of 3% hypertonic saline and recombinant human interferon (rhIFN) α-2b in the treatment of children with mild to moderate bronchiolitis. Methods: A total of 134 children with mild to moderate bronchiolitis hospitalized in department of pediatrics of Anqing Hospital Affiliated to Anhui Medical University from November2015 to April 2017 were randomly divided into three groups: children in the control group received atomization inhalation (salbutamol solution 0.5 mg+budsonide 0.5 mg) twice a day. Children in hypertonic saline group received additional atomization inhalation of 3% hypertonic saline 4 mL, 3 times a day every 4 hours based on the treatment of the control group. Children in interferon group received additional atomization inhalation of rhIFN α-2b (200,000 IU / kg each time) twice a day based on the treatment of the control group. The clinical severity scores before and after treatment in 5 days, adverse reactions, number of withdrew from the study in each group and the length of stay were recorded. Results: Among the 134 cases, 3 cases in the control group, 2 cases in hypertonic saline group and 2 cases in interferon group withdrew from the study because of treatment with additional drugs due to aggravation of the disease (P>0.05). Four cases in hypertonic saline group withdrew because of paroxysmal irritable cough, while no obvious adverse reactions were observed in interferon group or control group (P<0.05). Practically, 123 cases were enrolled in the clinical study, among which 40 cases in control group, 42 cases in hypertonic saline group and 41 cases in interferon group. The severity scores of hypertonic saline group were lower than that of interferon group from the 2nd to 4th day after treatment, and the differences were statistically significant (P<0.01). The severity scores of hypertonic saline group were lower than those of the control group from the 2nd to 5th day after treatment, and the differences were statistically significant (P<0.01). The severity scores of interferon group were lower than those of the control group on the 4th and 5th day after treatment and the differences were statistically significant ( P<0.01). The hospital stays of both hypertonic saline group and interferon group were shorter than that of the control group and the differences were statistically significant (P<0.05). Conclusion
: Atomization inhalation of 3% hypertonic saline and rhIFN α-2b can improve the condition of children with mild to moderate bronchiolitis. Both of them can shorten hospital stay, but the atomization inhalation of 3% hypertonic saline may cause irritable cough. |
| Key words: bronchiolitis hypertonic saline recombinant human interferon α-2b atomization inhalation |
